Long-term follow-up of Dutch childhood leukemia study group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991

Leukemia

Volumn 14, Issue 12, 2000, Pages 2240-2246

  Kamps, W A ^a,b   Veerman, A J P ^a,c   Van Wering, E R ^a   Van Weerden, J F ^a   Slater, R ^d,e   Van Der Does Van Den Berg, A ^a  

^a Dutch Childhood Leukemia Study Group   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e Dutch Workgroup on Cancer Genetics and Cytogenetics ^*

Author keywords

Childhood acute lymphoblastic leukemia; CNS prophylaxis; Long term outcome; NCI risk classification

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTARABINE; DEXAMETHASONE; DNA; DOXORUBICIN; FOLINATE CALCIUM; HLA DR ANTIGEN; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INFANT; INFORMATION PROCESSING; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEUROPROTECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SKULL IRRADIATION; SURVIVAL RATE; T CELL LEUKEMIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034518867     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401964     Document Type: Article

References (16)

1. Therapy results in five ALL-BFM studies since 1970. Complications of risk factors for prognosis
2. Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindersalter: Prognostische Bedeutung und praktische Anwendung
3. The treatment of childhood acute lymphoblastic leukemia
4. Minimal requirements for the diagnosis, classification and evaluation of the treatment of childhood ALL in the 'BFM Family' Cooperative Group
5. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients
6. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group
7. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM 86 without cranial radiotherapy: Results of DCLSG Protocol ALL-7 (1988-1991)
8. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
9. Proposals for the classification of the acute leukaemias
10. The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations
11. Storage of cerebrospinal fluid samples at room temperature
12. Diagnosis of meningeal involvement in childhood acute lymphoblastic leukemia: Cytomorphology and TdT
13. Update of the cytogenetic study of childhood non-high-risk acute lymphocytic leukemia at diagnosis in protocol VI of the Dutch Childhood Leukemia Study Group
14. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood
15. Role of cranial radiotherapy for childhood T cell acute lymphoblastic leukemia with high WBC count and good response to prednisone